Reference
1. Park SH, Chi HS, Cho YU, et al. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)positive acute myeloid leukemia patients. Leuk Res. 2013;37: 784-789.
2. Muller AM, Duque J, Shizuru JA, Lubbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene. 2008;27:5759-5773.
3. Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1RUNX1T1: Frequency and impact on clinical outcome. Leukemia. 2014;28:1449-1458.
4. Yu G, Yin C, Wu F, et al. Gene mutation profile and risk stratification in AML1ETO-positive acute myeloid leukemia based on nextgeneration sequencing. Oncol Rep. 2019; 42: 2333-2344.
Duployez N, Marceau‑Renaut A, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127: 2451‑2459. 6. Qin YZ, Zhu HH, Jiang Q, et al. Prevalence and prognostic significance of c‑KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large‑scale study from a single Chinese center. Leuk Res. 2014;38:1435‑1440.
7. Yu G, Yin C, Jiang L, et al. Amyloid precursor protein has clinical and prognostic significance in AML1ETOpositive acute myeloid leukemia. Oncol Lett. 2018;15: 917-925.
8. Klein K, Kaspers G, Harrison CJ,  et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015;33:4247-4258.
9. Abdel RH, Farrag SA, El-Attar IA. AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications. J Egypt Natl Canc Inst. 2007;19:39-47.
10. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127: 2391-2405.
Støve HK, Sandahl JD, Abrahamsson J, et al. Extramedullary leukemia in children with acute myeloid leukemia: A population‐based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Pediatr Blood Cancer. 2017;64(12). doi: 10.1002/pbc.26520.
12. Yu G, Yin C, Jiang L, et al. Amyloid precursor protein cooperates with C-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via PI3K/AKT signaling pathway. Oncol Rep. 2016;36:1626-1632.
13. Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826-2835.
14. Jiang L, Yu G, Meng W, et al. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumour Biol. 2013; 34: 629-636.
15. Jiang L, Meng W, Yu GP, et al. MicroRNA144 targets APP to regulate AML1/ETO+ leukemia cell migration via the pERK/cMyc/MMP2 pathway. Oncol lett. 2019; 18: 2034-2042.
16. Zhang MY, Zheng CY, Zou MM, et al. Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice. Neurobiol Aging. 2014;35:2713-2725.
17. Hansel DE, Rahman A, Wehner S, et al. Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res. 2003;63:7032-7037.
18. Ko SY, Lin SC, Chang KW, et al. Increased expression of amyloid precursor protein in oral squamous cell carcinoma. Int J Cancer. 2004;111:727-732.
19. Takayama K, Tsutsumi S, Suzuki T, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res. 2009;69:137-142.
20. Baldus CD, Liyanarachchi S, Mrózek K, et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA. 2004;101:3915-3920.
21. Wang W, Meng FY, Huang ZF, et al. Expression and role of amyloid precrusor protein gene in acute myeloid leukemia. Chin J Hematol. 2010;31:309-14 (In Chinese).
22. Rubnitz JE, Raimondi SC, Hallbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: A single institution’s experience. Leukemia. 2002;16:2072-2077.
23. Lan TY, Lin DT, Tien HF, et al. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol. 2009;122:238-246.
24. Byrd JC,Weiss RB, Arthur DC, at al.Extramedullary leukemia adversely affects hematologic complele remission rate and overall survival in patients with t(8;2 1)(q22;q22):results from Cancer and Leakemia Group B8461.J Clin Oncol. 1997; 15: 466-475.
25. Lai YY, Qiu JY, Jiang B, et al. Characteristics and prognostic factors of acute myeloid leukemia with t( 8; 21) ( q22; q22). Journal of Experimental Hematology. 2005; 13( 5) : 733- 740.
26. Felice MS, Zubizarreta PA, Alfaro EM, et al. Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma: a report from a single institution in Argentina. Cancer. 2000; 88(8):1939–1944.
27. Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer. 2007;48(4):393-398.
28. Voigt AP, Brodersen LE, Alonzo TA, et al. Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531. Haematologica. 2017;102:2058-2068.
29. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115:2372-2379.
30. Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paried diagnosis and relapse samples. Leukemia. 2008;22:303-307.
31. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027-1036.
32. Acute myeloid leukemia, Version 3.2020, 12/23/19 © 2019 National Comprehensive Cancer Network® (NCCN®). http://guide.medlive.cn.
33. Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guildlines for diagnosis and treatment of adult acute lyeloid leukemia (not APL) (2017). Chin J Hematol. 2017;38:177-184.